European Journal of Pediatrics

, Volume 153, Issue 9, pp 659–662

Interferon for chronic hepatitis C in patients cured of malignancy

Authors

  • S. Cesaro
    • Division of Haematology-Oncology, Department of PaediatricsUniversity of Padova
  • F. Rossetti
    • Division of Haematology-Oncology, Department of PaediatricsUniversity of Padova
  • L. Zanesco
    • Division of Haematology-Oncology, Department of PaediatricsUniversity of Padova
  • L. De Moliner
    • Second Division of Internal MedicineUniversity of Padova
  • F. Bortolotti
    • Second Division of Internal MedicineUniversity of Padova
  • C. Crivellaro
    • Division of Infectious DiseasesOspedale Civile of Padova
Original Paper

DOI: 10.1007/BF02190687

Cite this article as:
Cesaro, S., Rossetti, F., Zanesco, L. et al. Eur J Pediatr (1994) 153: 659. doi:10.1007/BF02190687

Abstract

Six patients with chronic hepatitis C who were cured of malignancy were treated with recombinant interferon-alpha at the dose of 4 MU/m2 for 12 months; the post-treatment follow up period was 12 months. Therapy was stopped within 6 months in three patients because of persistently abnormal alanine aminotransferase levels. In the remaining three patients, a complete normalization of alanine amnotransferase levels was obtained during treatment but it was not maintained after the end of interferon therapy. In addition, no patient cleared hepatitis C virus ribonucleic acid in serum. These results suggest that recombinant interferon is not effective in patients with chronic hepatitis C who were cured of a previous malignancy.

Key words

Chronic hepatitisHepatitis C virusChildhood malignancyRecombinant interferon-alpha

Abbreviations

ALT

alanine aminotransferase

Anti-HCV

hepatitis C virus antibodies

HBV

hepatitis B virus

HCV

hepatitis C virus

IFN

recombinant interferonalpha

RIBA II

recombinant immunoblotting assay second generation

Download to read the full article text

Copyright information

© Springer-Verlag 1994